Evidence map›Paper›PMID 29915163›Full record

ArticleAging2018

Five ETS family members, ELF-1, ETV-4, ETV-3L, ETS-1, and ETS-2 upregulate human leukocyte-associated immunoglobulin-like receptor-1 gene basic promoter activity.

Qizhi Cao, Shude Yang, Qing Lv, Yan Liu, Li Li, Xiaojie Wu, Guiwu Qu, Xiaoli He, Xiaoshu Zhang, Shuqin Sun and 4 more

Open access · greenAbstract read
In one paragraph

Article in Aging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Qizhi Cao *Department of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Shandong 264003, China.
Shude Yang *School of Agriculture, Ludong University, Shandong 264003, China.
Qing Lv *Anti-aging Research Institution, Binzhou Medical University, Shandong 264003, China.
Yan LiuDepartment of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Shandong 264003, China.
Li LiBeijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Xiaojie WuDepartment of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Shandong 264003, China.
Guiwu QuAnti-aging Research Institution, Binzhou Medical University, Shandong 264003, China.
Xiaoli HeThe People's Liberation Army 107 Hospital, Affiliated Hospital of Bin Zhou Medical University, Yantai 264002, China.
Xiaoshu ZhangDepartment of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Shandong 264003, China.
Shuqin SunSchool of Gerontology, Binzhou Medical University, Shandong 264003, China.
Boqing LiDepartment of Microbiology, School of Basic Medical Sciences, Binzhou Medical University, Shandong 264003, China.
Jing AnSchool of Medicine, University of California - San Diego, La Jolla, CA 92037, USA.
Tao HuDepartment of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Shandong 264003, China.
Jiangnan XueDepartment of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Shandong 264003, China.
Binzhou Medical University · CNBinzhou University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNLudong University · CNUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1), an immunoinhibitory receptor, is expressed on most types of hematopoietic cells and some tumor cells. LAIR-1 plays an inhibitory role in immune cell maturation, differentiation, and activation. LAIR-1 is also involved in some autoimmune diseases and tumors. However, the mechanism controlling the regulation of the LAIR-1 gene is still unknown. In order to elucidate the molecular mechanisms involved in LAIR-1 regulation, in the present study, we cloned and characterized the promoter region of LAIR-1 gene using a series of truncated promoter plasmids in luciferase reporter assays. Our results show that the basic core promoter of LAIR-1 is located within the region -256/-8 relative to the translational start site. Our further studies indicate that five ETS transcription factors: ELF-1, ETV-4, ETV-3L, ETS-1 and ETS-2, can up-regulate the LAIR-1 basic promoter activity. Of these, ETS-2 is the most effective transcription factor. Moreover, ETS-2 was confirmed to interact directly with the basic promoter of LAIR-1. This study presents the first description of regions/factors capable of up-regulation the promoter activity of LAIR-1. This new knowledge contributes to understanding of the molecular mechanisms involved in LAIR-1 associated immune regulation and diseases.

Indexed as

Adenovirus E1A ProteinsEphrin-A2Gene Expression RegulationHEK293 CellsHumansPromoter Regions, GeneticProto-Oncogene Protein c-ets-1Proto-Oncogene Protein c-ets-2Proto-Oncogene ProteinsProto-Oncogene Proteins c-etsReceptors, ImmunologicUp-RegulationAdenovirus E1A ProteinsEphrin-A2ETS1 protein, humanETS2 protein, humanETV3 protein, humanETV4 protein, humanleukocyte-associated immunoglobulin-like receptor 1Proto-Oncogene Protein c-ets-1Proto-Oncogene Protein c-ets-2Proto-Oncogene ProteinsProto-Oncogene Proteins c-etsReceptors, ImmunologicETS-2ETS transcription factorsLAIR-1Luciferasepromotertransfection

Identifiers

PMID29915163
PMCPMC6046229
OpenAlexW2809271790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.